Alzheimer’s disease biomarkers measured from finger-prick dried blood samples closely match standard plasma tests and predict ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Topline results from a phase 2b/3 clinical trial of ...

Phase 1 data shows sabirnetug (ACU193) is safe, reduces amyloid plaques, and supports ongoing Phase 2 trial for early Alzheimer’s disease. The press release implies that while there were positive ...

The majority of patients with early-stage disease Alzheimer’s disease (AD) had stable or improved cognition over roughly 1 year of treatment with lecanemab (Leqembi), a real-world analysis showed. The ...

Anavex Life Sciences Corp. announced significant findings from the ATTENTION-AD trial, indicating that long-term treatment with the oral drug blarcamesine (ANAVEX®2-73) improved cognition and ...

The kickoff to Super Bowl LX is nearly a year away, but NBCUniversal is already at work trying to tackle ad dollars for the glitzy sports event. NBCU has already indicated it will seek around $7 ...

INmune Bio, Inc. (INMB) recently reported results from its phase 2 MINDFuL study, evaluating the use of XPro for the treatment of patients with early Alzheimer's Disease [AD]. It was noted that the ...